<DOC>
	<DOCNO>NCT01049035</DOCNO>
	<brief_summary>The purpose study evaluate optimal vaccination schedule Quadrivalent Meningococcal ( A , C , Y W-135 ) Tetanus Protein Conjugate Vaccine ( TetraMen-T ) order provide effective protein conjugate quadrivalent meningococcal vaccine population high incidence disease . Objectives : - To describe safety profile TetraMen-T vaccine administer 5 different schedule concomitantly routine pediatric vaccination . - To describe immunogenicity profile TetraMen-T vaccine administer 5 different schedule concomitantly routine pediatric vaccination . - To describe immunogenicity profile select license pediatric vaccine ( Pentacel , Prevnar , M-M-RII Varivax ) administer either concomitantly without TetraMen-T vaccine .</brief_summary>
	<brief_title>A Study Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine ( TetraMen-T ) Infants Toddlers</brief_title>
	<detailed_description>Participants receive study vaccination begin age 2 , 6 , 12 month , depend assign schedule randomize group . All participant undergo safety immunogenicity assessment accord schedule assign group .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Groups 1 , 2 , 3 , 6 , 7 : Aged 42 89 day day inclusion ; Group 4 : Aged 6 month ( 180 day ± 14 day ) day inclusion ; Group 5 : Aged 12 month ( 365 day + 14 day ) day inclusion Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Informed consent form sign dated parent legally acceptable representative Participant parent/guardian able attend schedule visit comply trial procedure Group 4 : Prior receipt Pentacel Prevnar 2 4 month ; 1 2 dos rotavirus vaccine ; 2 3 previous dos hepatitis B vaccine Group 5 : Prior receipt Pentacel Prevnar 2 , 4 , 6 month ; 2 3 dos rotavirus vaccine ; 3 previous dos hepatitis B vaccine Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine 4 week follow trial vaccination , exception influenza vaccine , may receive 14 day TetraMenT vaccine Previous vaccination meningococcal disease either trial vaccine another vaccine Receipt blood bloodderived product past 30 day , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week ) Known personal maternal seropositivity human immunodeficiency virus ( HIV ) , hepatitis B vaccine , hepatitis C , report parent/guardian History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Thrombocytopenia , report parent/guardian Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination History seizures Personal family history GuillainBarré Syndrome ( GBS ) Chronic illness , opinion investigator , stage might interfere trial conduct completion Temporary contraindication resolve vaccination : Febrile illness ( temperature ≥38.0°C [ ≥100.4°F ] ) moderate severe acute illness/infection ( accord investigator judgment ) day vaccination Group 5 : Receipt oral inject antibiotic therapy within 72 hour prior study blood draw . Topical antibiotic antibiotic drop include exclusion criterion . ( Note : This apply group time , blood draw within 30 day initial visit . )</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>365 Days</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infection</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Tetravalent Meningococcal Vaccine</keyword>
</DOC>